Cargando…

Is EGFR expression altered following postoperative chemotherapy for colorectal adenocarcinoma?

BACKGROUND: There is immunohistochemical evidence to suggest that expression of epidermal growth factor receptor (EGFR) in primary colorectal adenocarcinoma predicts its expression in recurrent disease. This study investigates whether postoperative chemotherapy affects the degree of concordance betw...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalifa, Mahmoud A, Rowsell, Corwyn H, Gladdy, Rebecca, Ko, Yoo-Joung, Hanna, Sherif, Smith, Andy, Law, Calvin
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1705809/
https://www.ncbi.nlm.nih.gov/pubmed/17163999
http://dx.doi.org/10.1186/1477-7819-4-92
_version_ 1782131287063003136
author Khalifa, Mahmoud A
Rowsell, Corwyn H
Gladdy, Rebecca
Ko, Yoo-Joung
Hanna, Sherif
Smith, Andy
Law, Calvin
author_facet Khalifa, Mahmoud A
Rowsell, Corwyn H
Gladdy, Rebecca
Ko, Yoo-Joung
Hanna, Sherif
Smith, Andy
Law, Calvin
author_sort Khalifa, Mahmoud A
collection PubMed
description BACKGROUND: There is immunohistochemical evidence to suggest that expression of epidermal growth factor receptor (EGFR) in primary colorectal adenocarcinoma predicts its expression in recurrent disease. This study investigates whether postoperative chemotherapy affects the degree of concordance between EGFR statuses of the two tumors. METHODS: Thirty-three patients were identified from the files of Sunnybrook Health Sciences Center from July 1994 to June 2005. All patients had resection of their primary tumors and their distant recurrences. Eighteen patients received postoperative chemotherapy, 3 of which also received postoperative radiation therapy. Representative primary and recurrent tumor sections were stained using mouse anti-EGFR antibodies and only membranous staining of malignant cells was recorded. Results were reported as negative (no staining), 1+ (positivity in <50% of cells) or 2+ (positivity in >50% of cells). RESULTS: EGFR immunostaining in the 15 patients, who received no postoperative chemotherapy, was decreased in 3 recurrences, remained the same in 10 and increased in 2. In the group of 18 patients who received postoperative chemotherapy, EGFR immunostaining was decreased in 6 recurrences, remained the same in 9 and increased in 3 (p = 0.6598). In patients who received postoperative chemotherapy, the odds ratio for a recurrence to show lower levels of EGFR immunostaining compared to its originally resected primary was 4.75 (CI = 0.94 – 26.73). CONCLUSION: These preliminary data suggest that recurrences following postoperative chemotherapy are likely to have lower levels of EGFR expression compared to cases who receive no chemotherapy. Although the difference of immunostaining profiles between the two groups was not statistically significant, this observation might impact the management of these patients by targeted biologic therapies and its practical implications need further validation in larger series.
format Text
id pubmed-1705809
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-17058092006-12-19 Is EGFR expression altered following postoperative chemotherapy for colorectal adenocarcinoma? Khalifa, Mahmoud A Rowsell, Corwyn H Gladdy, Rebecca Ko, Yoo-Joung Hanna, Sherif Smith, Andy Law, Calvin World J Surg Oncol Research BACKGROUND: There is immunohistochemical evidence to suggest that expression of epidermal growth factor receptor (EGFR) in primary colorectal adenocarcinoma predicts its expression in recurrent disease. This study investigates whether postoperative chemotherapy affects the degree of concordance between EGFR statuses of the two tumors. METHODS: Thirty-three patients were identified from the files of Sunnybrook Health Sciences Center from July 1994 to June 2005. All patients had resection of their primary tumors and their distant recurrences. Eighteen patients received postoperative chemotherapy, 3 of which also received postoperative radiation therapy. Representative primary and recurrent tumor sections were stained using mouse anti-EGFR antibodies and only membranous staining of malignant cells was recorded. Results were reported as negative (no staining), 1+ (positivity in <50% of cells) or 2+ (positivity in >50% of cells). RESULTS: EGFR immunostaining in the 15 patients, who received no postoperative chemotherapy, was decreased in 3 recurrences, remained the same in 10 and increased in 2. In the group of 18 patients who received postoperative chemotherapy, EGFR immunostaining was decreased in 6 recurrences, remained the same in 9 and increased in 3 (p = 0.6598). In patients who received postoperative chemotherapy, the odds ratio for a recurrence to show lower levels of EGFR immunostaining compared to its originally resected primary was 4.75 (CI = 0.94 – 26.73). CONCLUSION: These preliminary data suggest that recurrences following postoperative chemotherapy are likely to have lower levels of EGFR expression compared to cases who receive no chemotherapy. Although the difference of immunostaining profiles between the two groups was not statistically significant, this observation might impact the management of these patients by targeted biologic therapies and its practical implications need further validation in larger series. BioMed Central 2006-12-12 /pmc/articles/PMC1705809/ /pubmed/17163999 http://dx.doi.org/10.1186/1477-7819-4-92 Text en Copyright © 2006 Khalifa et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Khalifa, Mahmoud A
Rowsell, Corwyn H
Gladdy, Rebecca
Ko, Yoo-Joung
Hanna, Sherif
Smith, Andy
Law, Calvin
Is EGFR expression altered following postoperative chemotherapy for colorectal adenocarcinoma?
title Is EGFR expression altered following postoperative chemotherapy for colorectal adenocarcinoma?
title_full Is EGFR expression altered following postoperative chemotherapy for colorectal adenocarcinoma?
title_fullStr Is EGFR expression altered following postoperative chemotherapy for colorectal adenocarcinoma?
title_full_unstemmed Is EGFR expression altered following postoperative chemotherapy for colorectal adenocarcinoma?
title_short Is EGFR expression altered following postoperative chemotherapy for colorectal adenocarcinoma?
title_sort is egfr expression altered following postoperative chemotherapy for colorectal adenocarcinoma?
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1705809/
https://www.ncbi.nlm.nih.gov/pubmed/17163999
http://dx.doi.org/10.1186/1477-7819-4-92
work_keys_str_mv AT khalifamahmouda isegfrexpressionalteredfollowingpostoperativechemotherapyforcolorectaladenocarcinoma
AT rowsellcorwynh isegfrexpressionalteredfollowingpostoperativechemotherapyforcolorectaladenocarcinoma
AT gladdyrebecca isegfrexpressionalteredfollowingpostoperativechemotherapyforcolorectaladenocarcinoma
AT koyoojoung isegfrexpressionalteredfollowingpostoperativechemotherapyforcolorectaladenocarcinoma
AT hannasherif isegfrexpressionalteredfollowingpostoperativechemotherapyforcolorectaladenocarcinoma
AT smithandy isegfrexpressionalteredfollowingpostoperativechemotherapyforcolorectaladenocarcinoma
AT lawcalvin isegfrexpressionalteredfollowingpostoperativechemotherapyforcolorectaladenocarcinoma